Related Experiment Video

Updated: Aug 29, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Canertinib pfizer

Carlos Maria Galmarini1

  • 1University of Lyon, INSERM 590. 8, Avenue Rockefeller, 69373 LYON CEDEX 08, France. fgalma@rockefeller.univ-lyon1.fr

Idrugs : the Investigational Drugs Journal
|January 20, 2004
PubMed

Insights

Canertinib is an orally available EGFR tyrosine kinase inhibitor developed by Pfizer Inc. It is an analog of PD-169414 and shows potential for cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Epidermal Growth Factor Receptor (EGFR) signaling is implicated in various cancers.
  • Targeting EGFR tyrosine kinases is a validated therapeutic strategy.

Purpose of the Study:

  • To introduce Canertinib, an investigational EGFR tyrosine kinase inhibitor.
  • To highlight its development by Pfizer Inc. as a potential cancer therapeutic.

Main Methods:

  • Canertinib is described as a water-soluble, orally available analog of PD-169414.
  • Its development is being conducted by Pfizer Inc.

Main Results:

  • Canertinib exhibits properties suitable for oral administration.
  • It functions as an inhibitor of EGFR tyrosine kinase activity.

Conclusions:

  • Canertinib represents a promising new agent for cancer therapy.
  • Further clinical development is anticipated.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...